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Hypoxia in the microenvironment of many solid tumours is an
important determinant of malignant progression. The ISR (integ-
rated stress response) protects cells from the ER (endoplasmic
reticulum) stress caused by severe hypoxia. Likewise, autophagy
is a mechanism by which cancer cells can evade hypoxic cell
death. In the present paper we report that the autophagy-initiating
kinase ULK1 (UNC51-like kinase 1) is a direct transcriptional
target of ATF4 (activating transcription factor 4), which drives
the expression of ULK1 mRNA and protein in severe hypoxia and
ER stress. We demonstrate that ULK1 is required for autophagy
in severe hypoxia and that ablation of ULK1 causes caspase-
3/7-independent cell death. Furthermore, we report that ULK1
expression is associated with a poor prognosis in breast cancer.
Collectively, the findings of the present study identify transcrip-
tional up-regulation of ULK1 as a novel arm of the ISR, and
suggest ULK1 as a potentially effective target for cancer therapy.
Key words: autophagy, endoplasmic reticulum stress, hypoxia,
integrated stress response, UNC51-like kinase 1 (ULK1),
unfolded protein response (UPR).
INTRODUCTION
The microenvironment of a solid tumour is both hostile and
heterogeneous, characterized by extremes in pH, metabolite
concentrations and, in particular, partial pressure of oxygen. Rapid
tumour growth leads to oxygen gradients in vivo [1,2]. Oxygen
levels can be extremely low, and up to 35% of tumour cells
have levels below 0.1% O2 [3]. Patients with hypoxics
tumour have a significantly worse disease-free and overall survival
compared with patients with well-oxygenated tumours [4,5].
Several intracellular signalling pathways known to be involved
in cancer progression and adaptation are activated by hypoxia,
including the well-described HIFs (hypoxia-inducible factors)
[6,7]. In addition, in prolonged or severe hypoxia (<0.01% O2),
dysfunctional protein folding in the lumen of the ER (endoplasmic
reticulum) leads to the activation of the UPR (unfolded protein
response) [8,9]. The UPR sensors PERK [PKR (double-stranded-
RNA-dependent protein kinase)-like ER kinase], IRE1 (inositol-
requiring enzyme 1) and ATF (activating transcription factor)
6 detect the accumulation of unfolded proteins, and elicit an
adaptive response to overcome this stress [10].
The cytoplasmic kinase domain of activated PERK
phosphorylates eIF2α (eukaryotic initiation factor 2α) and
thus represses global mRNA translation [11,12], reducing the
burden on the ER protein folding machinery. In addition, eIF2α
phosphorylation enables the selective translation of a subset of
transcripts such as the key transcriptional effector ATF4 [13,14].
ATF4 regulates the expression of genes involved in translation,
amino acid import and metabolism, redox, protein secretion,
glucose metabolism, DNA damage, lipogenesis, angiogenesis,
and apoptosis in what has been termed the ISR (integrated stress
response) [9,15–18]. Studies have highlighted the importance of
the ISR in cancer cell survival and tumour maintenance. Data
indicate that ATF4 and the ISR promote the survival of hypoxia,
nutrient deprivation and oxidative stress in vitro [9,19–22] and
tumour progression in mouse xenograft models [19,23,24].
Cancer cells rely on autophagy to survive intratumoral hypoxia,
metabolic stress and starvation, and to resist radiotherapy
[19,21,22,25]. Intriguingly, pancreatic cancer cells and H-Ras-
expressing tumour cells have elevated levels of basal autophagy,
and appear to rely on autophagy to maintain high levels of
oxidative phosphorylation and a pool of viable mitochondria, in a
phenomenon that has been termed ‘autophagy addiction’ [26–28].
We and others have demonstrated that some components of
the autophagic machinery are subject to ISR regulation. Severe
hypoxia and ER stress induce the transcription of the essential
autophagy genes MAP1LC3B (microtubule-associated protein
1 light chain 3β) and ATG5 (autophagy-related 5) through
the activity of ATF4 and CHOP [C/EBP (CCAAT/enhancer-
binding protein)-homologous protein] respectively [19,21]. This
up-regulation was shown to be crucial for maintaining high levels
of autophagic flux in persistent hypoxia, and thus promotes
cell survival. Similarly, we have demonstrated that ATF4 and
autophagy are crucial for the resistance of cancer cells to
bortezomib [29]. In the present study, we demonstrate that ATF4
drives the transcriptional induction of the autophagy-initiating
kinase ULK1 (UNC51-like kinase 1) in response to severe
hypoxia and ER stress. Furthermore, we show that ULK1 and
ATF4 are crucial for autophagy, mitophagy and cancer cell
survival in both normoxia and severe hypoxia, and that loss of
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box 1; ISR, integrated stress response; LC3, microtubule-associated protein light chain 3; MAP1LC3B, microtubule-associated protein 1 light chain 3β;
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ULK1 promotes necrotic cell death. Finally, we show that elevated
ULK1 mRNA expression is associated with poor prognosis in a
specific group of breast cancer patients.
MATERIALS AND METHODS
Reagents and cell culture
TG (thapsigargin) (catalogue number 586005), TN (tunicamycin)
(catalogue number 654380), MG115 (catalogue number 474780),
bafilomycin A1 (catalogue number 196000) and pepstatin A
(catalogue number 516481) were obtained from Calbiochem,
and E64D (catalogue number E8640) and chloroquine (catalogue
number C6628) were obtained from Sigma–Aldrich. Bortezomib
was a gift from Millennium Pharmaceuticals. A431, MCF7,
HT29, MDA-MB-231, HCT116 and U87 cell lines were provided
by Cancer Research UK and were cultured in DMEM (Dulbecco’s
modified Eagle’s medium; Invitrogen, catalogue number 11965)
with 10% (v/v) FBS (fetal bovine serum), supplemented with
0.5 μg/ml penicillin/streptomycin (Invitrogen, catlogue number
15070) and 4 mM L-glutamine (Invitrogen, catalogue number
25030). Cell lines were incubated at 37 ◦C in a non-humidified
incubator with 95% air supplemented with 5% CO2.
Hypoxic incubations
For incubations in severe hypoxia (<0.01% O2), the InVivO2
400 humidified gas-sorted incubator with a glove box (Ruskin)
was used. A gas mix of 5% H2, 5% CO2 and 90% N2 was fed
into the system. A palladium catalyst maintained near-zero O2
concentrations by reducing trace O2. For incubations in moderate
hypoxia (0.1% O2), a Heto-Holten CellHouse 170 incubator (RS
Biotech) was used.
Transfections
Transfections of siRNA (small interfering RNA) and DNA were
performed with HiPerfect (Qiagen, catalogue number 301704)
and FuGENE® 6 (Roche, catalogue number 11814443001)
transfection reagents respectively, as described previously [29].
The specific siRNA sequences used can be found in Supplement-
ary Table S1 (at http://www.biochemj.org/bj/449/bj4490389add.
htm).
Western blot analysis
Western blots were prepared as described previously [29].
Antibodies used are described in the Supplementary Online data
(at http://www.biochemj.org/bj/449/bj4490389add.htm).
RT-qPCR (real-time quantitative PCR)
In RT-qPCR experiments, the methods used by us for extraction,
quantification and evaluation of the quality of RNA were as
described previously [30]. Data from RT-qPCR experiments
were normalized to tubulin α6. The sequences of primers used
are listed in Supplementary Table S2 (at http://www.biochemj.
org/bj/449/bj4490389add.htm).
Immunocytochemistry for LC3 (microtubule-associated protein
light chain 3)
Staining for LC3-positive foci was performed as described
previously [29].
ULK1 activity assays
Endogenous ULK1 protein was immunoprecipitated from A431
and MCF7 cells and used in subsequent analysis of MBP (myelin
basic protein) phosphorylation. A detailed method is given in the
Supplementary Online Data.
ChIP (chromatin immunoprecipitation)
The ChIP assays were performed using the EZ ChIP Chromatin
Immunoprecipitation kit (Millipore, catalogue number 17-371),
according to the manufacturer’s instructions, using 5 μg of rabbit
anti-ATF4 antibody. The sequences of primers used for RT-qPCR
of promoter fragments are shown in Supplementary Table S3 (at
http://www.biochemj.org/bj/449/bj4490389add.htm).
Imagestream® analysis of autophagy
MCF7 cells were stained with a live/dead marker, Lysotracker
Red, and anti-LC3 antibodies and fixed and analysed for
autophagic flux using Imagestream® flow-cytometric methods as
described previously [31].
Flow cytometry
MCF7 and A431 cells were stained with Alexa Fluor® 647-
conjugated anti-AV (annexin-V) antibody (Invitrogen, catalogue
number A23204) and cell death was quantified by flow cytometry
according to the manufacturer’s protocol and as decribed
previously [32] using a Cyan ADP Flow Cytometer (Dako).
Mitochondrial fluorescence was measured by first staining
cells with Mitotracker Red FM (Invitrogen, catalogue number
M22425). Mean fluorescence was used to assess changes in
mitochondrial mass, as described previously [33].
Clonogenic assays
Clonogenic assays were performed to assess survival in severe
hypoxia following transfection with siRNA molecules specific for
ATF4 or ULK1, as described previously [21]. For the counting of
colonies, the ColCount Colony Counter (Oxford Optronix) was
used.
Luminescent assays
Caspase 3/7 protease activity was analysed using the
CaspaseGlow® 3/7 assay (Promega, catalogue number G8091)
according to the manufacturer’s protocol. Similarly, ATP levels
were measured using the Cell-Titer Glo® Luminescent Cell
Viability assay (Promega, catalogue number G7570) according
to the manufacturer’s protocol.
Immunohistochemistry
Immunohistochemistry was performed on spheroids to assess
clinically relevant markers of hypoxia, cell death and proliferation
as described previously [29].
Three-dimensional growth assay
Rapid generation of single-tumour spheroids was achieved using
the method developed by Ivascu and Kubbies [34]. An Axiovert
135 Microscope (Zeiss) was used for image capture and ImageJ
version 1.43 (NIH) was used to calculate spheroid volume.
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HMGB1 (high-mobility group box 1) ELISA
An HMGB1 sandwich ELISA from IBL International was used
to quantitatively determine the levels of HMGB1 in the cell
culture medium of cells undergoing necrosis, according to the
manufacturer’s protocol.
Survival analysis
For survival analysis, a published series of breast cancer patients
was used. mRNA was extracted from tumour samples, and
expression profiling was performed as described previously [35].
Full details are given in the Supplementary Online Data. Written
informed consent was obtained and all clinical investigations
were conducted according to the ethical standards and principles
expressed in the Declaration of Helsinki. Ethical approval was
obtained from the local research ethics committee.
RESULTS
ULK1 mRNA and protein levels increase in response to severe
hypoxia, ER stress, moderate hypoxia and anti-angiogenic therapy
In previous work, we identified hypoxia- and ATF4-dependent
genes by microarray analysis [21]. The top 25 of these genes
were validated by RT-qPCR analysis and published [21]. Further
analysis of our data revealed that ULK1 mRNA was increased
1.76-fold by severe hypoxia (P = 0.001) and then reduced to 0.60-
fold after knockdown of ATF4 (P = 0.004).
To confirm the microarray results identifying ULK1 as a
hypoxia-inducible gene, a panel of cell lines were exposed
to severe hypoxia for increasing periods of time and ULK1
mRNA levels were assessed by RT-qPCR. In A431, HT29
and MCF7 cells, ULK1 mRNA was seen to increase after
12 h in severe hypoxia, and to reach a maximum after 48 h
(Figures 1A–1C). A431 and HT29 cells exhibited close to 30-fold
increases in ULK1 mRNA (P < 0.05 and P < 0.01 respectively),
whereas MCF7 cells exhibited a more modest increase of 5-fold
(P < 0.01).
Consistent with the mRNA data, ULK1 protein levels
in A431 and HT29 cells increased markedly after 12 and 6 h in
severe hypoxia respectively (Figures 1D and 1E). In contrast,
in MCF7 cells ULK1 protein levels were found to be high in
normoxia, and then decreased after 48 h in severe hypoxia
(Figure 1F). In U87 and HCT116 cells, ULK1 protein peaked
at 6 h and then rapidly decreased with prolonged exposure
to severe hypoxia (Supplementary Figures S1A and S1B at
http://www.biochemj.org/bj/449/bj4490389add.htm).
Maximal induction of ULK1 mRNA and protein was preceded
by the accumulation of ATF4 protein (Figures 1A–1F). As
reported previously [19,21], LC3-II protein levels increased
markedly after 12–24 h in severe hypoxia, indicating that
autophagy was increased in this condition. Likewise, the
expression of the ISR target gene CHOP showed an mRNA
and protein expression profile that mimicked that of ULK1
(Supplementary Figures S1C–S1E).
To confirm that LC3-II protein levels were indicative of
increased autophagic flux rather than decreased lysosomal
degradation, p62 protein levels were examined. Indeed, severe
hypoxia resulted in increased degradation of p62 protein in concert
with LC3-II protein induction, whereas LC3-I remained constant
throughout (Figures 1G and 1H).
Similarly, when A431 cells were exposed to TG or TN,
potent stimulators of the ISR and autophagy [36], ATF4 protein
accumulated after 2 h and was followed by ULK1 protein
expression after 24 or 6 h respectively (Figures 1I and 1J). When
A431 cells were exposed to moderate hypoxia (0.1% O2), a
similar pattern of induction was observed (Figure 1K), indicating
that this phenotype is not limited to severe hypoxia.
To assess whether ULK1 may be induced by intratumoral
hypoxia, mRNA was isolated from U87 tumour xenografts treated
with PBS or bevacizumab [humanized anti-VEGF (vascular
endothelial growth factor) antibody], a treatment well known
to reduce intratumoral oxygen levels [37,38]. ULK1 mRNA
levels were increased nearly 2-fold by bevacizumab treatment
(P < 0.001), in a fashion similar to CHOP (Supplementary Figure
S2A at http://www.biochemj.org/bj/449/bj4490389add.htm).
Similarly, when A431 cells were grown as spheroids in vitro,
ULK1 protein was found to accumulate after 3 days, and to reach
a maximum after 6 days growth, correlating with expression of
ATF4 and LC3-II (Supplementary Figure S2B). These spheroids
were confirmed to be hypoxic by staining for pimonidazole, CAIX
(carbonic anhydrase IX) and CHOP (Supplementary Figure S2C).
As mentioned above, MCF7 cells exposed to severe hypoxia
strongly induced ULK1 mRNA, although ULK1 protein levels
were seen to decrease. Interestingly, proteasome inhibition
with bortezomib or MG115 partially blocked the reduction
in ULK1 caused by prolonged exposure to severe hypoxia
(Supplementary Figure S3A at http://www.biochemj.org/bj/449/
bj4490389add.htm), whereas inhibitors of the lysosome or
caspases failed to rescue ULK1 expression (Supplementary
Figures S3B and S3C).
Severe hypoxia and ER stress induce ULK1 in an ATF4-dependent
manner
Our microarray analysis identified ULK1 as a transcriptional
target of ATF4 [21]. To confirm this result, A431 and MCF7
cells were treated with siRNA to deplete ATF4. In both cell
lines, this treatment reduced ATF4 protein by at least 50%
after exposure to severe hypoxia (Figures 2A and 2C). ATF4
knockdown reduced CHOP protein (Figures 2A and 2C) and
mRNA induction (Supplementary Figures S4A and S4B at
http://www.biochemj.org/bj/449/bj4490389add.htm), indicating
that the transcriptional activity of ATF4 was attenuated. Similarly,
ULK1 protein expression in both A431 and MCF7 cells was
abrogated in both severe hypoxia and normoxia (Figures 2A
and 2C), as was ULK1 mRNA induction (Figures 2B and
2D) (P < 0.05 and P < 0.01 for A431 and MCF7 respectively).
Likewise, the accumulation of ULK1 protein caused by TG or
TN treatement was completely blocked when A431 cells were
first depleted of ATF4 by RNAi (RNA interference) (Figure 2E).
Interestingly, however, ectopic expression of ATF4 in normoxia
was not sufficient to induce the expression of ULK1 in A431 cells
to the levels seen in severe hypoxia (Supplementary Figure S5 at
http://www.biochemj.org/bj/449/bj4490389add.htm).
ATF4 binds directly to the promoter region of ULK1
Using the Genomatix® online software suite, we were able
to identify several putative CREB (cAMP-response-element-
binding protein)/ATF-binding sites (containing the TGACG core
sequence) in the ULK1 promoter. Thus, to determine whether
ATF4 binds directly to the promoter region of ULK1, ChIP was
performed using antibodies specific for ATF4.
Using RT-qPCR primers spanning the region 2000 bp upstream
of the transcription start site, the first exon and 500 bp
downstream of translation start (Figure 2F), we observed that
ATF4 ChIP samples showed the greatest enrichment in fragments
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 1 ULK1 is induced by ER stress and hypoxia in vivo and in vitro
A431, HT29 and MCF7 cells were exposed to severe hypoxia (<0.01 % O2) for the times indicated, after which time cells were harvested and analysed by RT-qPCR (A–C) or Western blotting (D–H)
using the primers and antibodies indicated. A431 cells were treated with 300 nM TG (I), 5 μg/ml TN (J) or exposed to moderate hypoxia (0.1 % O2) (K) and similarly analysed. The vertical line in
(K) indicates the point where the LC3 blot was cut. *P < 0.05 and **P < 0.01 respectively.
corresponding to the CREB site spanning − 306 bp to − 285 bp
relative to the ATG of exon one (Figure 2G). Furthermore, the
signal obtained from this primer set increased with exposure to
severe hypoxia, reflecting increased ATF4 binding with severe
hypoxia (Figure 2H). A previously published set of primers
designed against the CHOP promoter was used as a positive
control [19].
Severe hypoxia increases cellular ULK1 kinase activity through
both transcriptional and post-translational mechanisms
To date, most work has focused on post-translational regulation
of the specific activity of ULK1, demonstrating an important
role for AMPK (AMP-activated protein kinase)- and mTOR
(mammalian target of rapamycin)-mediated phosphorylation of
ULK1 in fasting and fed states respectively [39–43], rather
than the transcriptional regulation of total ULK1 levels. Thus,
having found that ULK1 mRNA up-regulation by ATF4 results in
increased protein expression in A431 cells but not in MCF7 cells,
we next sought to assess the total and specific activity of ULK1 in
each case.
The total immunoprecipitated ULK1 activity total P-MBP (P-
indicates phosphorylated protein)] from A431 cells increased
by 103% after 24 h in severe hypoxia (Figure 3A), although,
interestingly, the specific ULK1 activity (normalized to protein
expression) was 35% lower (Figure 3B). Thus, in spite
of decreased enzymatic activity, the ATF4-mediated increase
in ULK1 protein led to increased ULK1 activity and autophagy in
severe hypoxia. In MCF7 cells, on the other hand, although ULK1
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Figure 2 ATF4 binds directly to the ULK1 promoter to drive ULK1 expression in severe hypoxia or due to ER stress
A431 (A and B) or MCF7 (C and D) cells were transfected with siRNA against ATF4 (ATF4) or a scrambled control sequence (SCR) overnight and exposed to severe hypoxia (A) or normoxia (N)
the following day. After 12, 24 or 48 h, cells were harvested for analysis by Western blotting or RT-qPCR using the antibodies and primers indicated. *P < 0.05, **P < 0.01 and ***P < 0.001
respectively. (E) A431 cells were similarly transfected and then untreated (UTR) or treated with 300 nM TG or 5 μg/ml TN for 24 h before harvesting and analysis by Western blotting. MCF7 cells
were exposed to severe hypoxia and then processed for ATF4 ChIP. Primers sets (represented by grey bars) were designed spanning the region 2000 bp upstream of the transcription start site, the
first exon and 500 bp downstream of the translation start containing two putative ATF/CREB-binding sites. (F) Locations of primer pairs used for RT-qPCR analysis following ChIP. ATG indicates
the translation start site in exon 1. // indicates large gaps upstream and downstream of the ULK1 gene. CHR12 indicates primers designed against an upstream region on chromosome 12.
(G) RT-qPCR was performed to analyse the enrichment of these ULK1 promoter fragments in the hypoxic samples. CHOP indicates a previously published primer set for the CHOP promoter [19].
(H) RT-qPCR against the region corresponding to primer set #3 showed hypoxia-dependent enrichment of the ATF4-pulldown samples relative to the IgG controls. Data shown are from a single
ChIP, in which three independent dishes were pooled for each time point. Two such independent experiments were performed.
protein did not accumulate in severe hypoxia, its specific activity
increased by 115% after 12 h in severe hypoxia (P < 0.05)
(Figure 3B), yielding an overall increase in total ULK1 activity of
nearly 81% at this time point (P < 0.05) (Figure 3A). However,
this increase in ULK1 activity was transient and, by 24 h in severe
hypoxia, both specific and absolute ULK1 activity had decreased
to normoxic levels (Figures 3A and 3B).
These changes in the activity of ULK1 were associated with
increased AMPK signalling, as reflected by the increased level of
P-AMPK and its products P-ACC (acetyl-CoA carboxylase) and
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 3 ULK1 activity increases with severe hypoxia and is dependent on ATF4
A431 or MCF7 cells were exposed to severe hypoxia for 12 or 24 h, or with 100 nM rapamycin for 24 h, after which time cells were harvested and lysates prepared. An ULK1-specific antibody
was used to immunoprecipitate endogenous ULK1, and an in vitro ULK1 kinase activity was performed using MBP as a substrate. (A) Total immunoprecipitated ULK1 activity was calculated as
MBP phosphorylation normalized to the control. (B) Specific ULK1 activity was calculated as the ratio of MBP phosphorylation to ULK1 protein (densitometry), normalized to the control. (C and D)
Alternatively, lysates were subjected to analysis by Western blotting, using the antibodies indicated. (E) A431 cells stably expressing an inducible shRNA construct for ATF4 (ATF4) or a non-silencing
control (NS) were treated with doxycyclin for 2 days and then exposed to severe hypoxia for the times indicated. Total immunoprecipitated ULK1 activity was similarly quantified.
P-Raptor (regulatory associated protein of mTOR), and decreased
mTOR signalling, as reflected by decreased P-p70S6K (S6 kinase)
(Figures 3C and 3D). Strikingly, severe hypoxia also caused a
downward shift of the ULK1 band, which may be indicative
of hyper-dephosphorylation, as observed previously in starvation
[39].
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Figure 4 ULK1 is required for hypoxia-induced autophagy
A431 (A and C) or MCF7 (B and D) cells were transfected with siRNA against ULK1 (U), ATF4 (A) or a scrambled control sequence (S) overnight and exposed to severe hypoxia the next day for the
times indicated. (A and B) Cells were harvested for analysis by Western blotting using the antibodies indicated. (C and D) Cells were fixed and stained for LC3 (green) and counterstained with DAPI
(4′ ,6-diamidino-2-phenylindole) (blue). (E) MCF7 cells were transfected with siRNA against ULK1 or a scrambled control sequence (SCR) overnight and exposed to severe hypoxia the next day. At
24 h later, cells were stained for LC3 (green) and lysosomes (red), and fixed for Imagestream® analysis. (F) Histogram indicating co-localization of LC3 with lysosomes with bright detail similarity
(BDS)>2. (G) Alternatively, Mitotracker Red FM dye was added to live cells and cells were analysed by flow cytometry. Mean fluorescence was normalized to the normoxic control. N, normoxia; A,
severe hypoxia. ***P < 0.001.
To confirm the role of ATF4 in the transcriptional regulation
of ULK1 activity, A431 cells expressing an inducible lentiviral
shRNA (short hairpin RNA) sequence against ATF4 were treated
with doxycycline to silence ATF4 and then exposed to severe
hypoxia. ATF4 was depleted at least 80% by this treatment,
which caused a 50% reduction in ULK1 protein (Supplementary
Figure S6C at http://www.biochemj.org/bj/449/bj4490389add.
htm) and total immunoprecipitated ULK1 activity (P < 0.05)
(Figure 3E) after 36 h in severe hypoxia, despite no change in the
specific activity of ULK1 (Supplementary Figure S6D).
ULK1 is required for hypoxia-induced autophagy and mitophagy
To investigate the requirement for ULK1 in hypoxia-induced
autophagy, we depleted ULK1 using RNAi by 90%
(Supplementary Figure S7A at http://www.biochemj.org/bj/449/
bj4490389add.htm), and exposed A431 and MCF7 cells to severe
hypoxia. Indeed, knockdown of ULK1 severely reduced the
accumulation of LC3-II protein (the lipidated form of LC3,
a marker for autophagy) in A431 cells (Figure 4A) and to a
lesser extent in MCF7 cells (Figure 4B) in severe hypoxia.
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Likewise, ULK1 knockdown resulted in the accumulation of p62
protein after 24 h in severe hypoxia, indicating that ablation of
ULK1 resulted in reduced autophagic flux (Figures 4A and 4B).
Knockdown of ATF4, was less consistent, and even resulted in
increased levels of autophagy in some cases.
Staining revealed that ULK1 knockdown abrogated the
formation of LC3-positive autophagosomes in both cell
lines (Figures 4C and 4D). Likewise, cells depleted of
ULK1 failed to accrue autophagosomes in the presence
of chloroquine (an inhibitor of autophagosome fusion with
lysosmes) (Supplementary Figure S7B), again indicating that
ULK1 is required for the initiation of autophagy in severe hypoxia.
Furthermore, through the use of Imagestream® analysis of
autophagic flux [31] (co-localization of endogenous LC3 protein
and lysosomal stain), we found that ablation of ULK1 reduced
flux in MCF7 cells by 90% in severe hypoxia (P < 0.001) and,
intriguingly, by more than 80% in normoxia (P < 0.001)
(Figures 4E and 4F). Thus ULK1 is involved in both basal
autophagy and hypoxia-induced autophagy.
ULK1 has been shown previously to play an important role
in the regulation of mitophagy in starvation and red blood
cell maturation [33,43]. When mitochondrial mass was assessed
by flow cytometry, it was found that depletion of ULK1 or
ATF4 increased mean mitochondrial fluorescence by 40% and
20% respectively in both normoxia and hypoxia (P < 0.001)
(Figure 4G), suggesting that ULK1 and ATF4 are required for
both constitutive and hypoxia-induced mitophagy.
ULK1 and ATF4 are required for growth and survival in normoxia
and severe hypoxia
Having established that ULK1 is required for autophagy and
mitophagy in both normoxia and severe hypoxia, we next sought
to assess the effects of their loss on cell death. Depletion of ULK1
by RNAi markedly increased AV staining in A431 and MCF7 cells
in both normoxia and severe hypoxia (P < 0.001) (Figures 5A
and 5B). Depletion of ULK1 and ATF4 reduced clonogenicity
by 65% and 80% respectively in both normoxia and severe
hypoxia (P < 0.001) (Figure 5C). Likewise, knockdown of ULK1
or ATF4 in severe hypoxia reduced cellular ATP levels by more
than 75% (Figure 5D).
To determine whether the effector caspases were activated by
ablation of ULK1 or ATF4, caspase 3/7 activity was measured.
Loss of ATF4 in A431 cells nearly doubled the observed
caspase 3/7 activity, indicating that apoptosis was being activated
(P < 0.001) (Figure 5E). On the other hand, ULK1 knockdown
actually reduced caspase 3/7 activity in both normoxia and severe
hypoxia (P < 0.01 and P < 0.001) (Figure 5E), suggesting that cell
death in this case is due to a caspase-3/7-independent mechanism,
such a necrosis.
One common marker for necrosis is HMGB1, an architectural
chromatin-binding factor [44–46]. Indeed, knockdown of ULK1
or ATF4 in A431 cells exposed to normoxia or severe hypoxia
resulted in an increase in HMGB1 in the medium (Figure 5F) and
decreased intracellular HMGB1 (Figure 5G). This result implied
that knockdown of either ULK1 or ATF4 results in caspase-3/7-
independent cell death, although it is not possible to identify the
mechanism as necrosis without further study.
Further evidence for non-apoptotic cell death was found when
cell morphology was examined in spheroids. Spheroids derived
from ATF4-knockdown cells showed a high degree of nuclear
fragmentation and more caspase 3 cleavage than the scrambled
control, whereas spheroids formed from the ULK1-knockdown
cells showed almost no nuclear fragmentation and less caspase 3
cleavage than the scrambled control (Supplementary Figure S8A
at http://www.biochemj.org/bj/449/bj4490389add.htm).
Depletion of ULK1 or ATF4 reduces spheroid growth
We next assessed the effect of ULK1 or ATF4 knockdown on
growth in a three-dimensional spheroid model [34]. Spheroids
derived from A431 cells depleted of ULK1 or ATF4 showed
significantly retarded growth (P < 0.01) (Figures 6A and 6B).
ULK1- and ATF4-depeleted spheroids harvested on day 3
contained 84 and 90% AV-positive cells respectively, whereas
control spheroids contained 26% AV-positive cells (P < 0.01)
(Figure 6C). Staining for pimonidazole, CAIX and CHOP
indicated that the ULK1- and ATF4-knockdown spheroids were
much less hypoxic than the scrambled controls (Figure 6D).
Staining for Ki67, a marker of proliferation, showed no difference
between groups (Figure 6D).
To determine whether a similar effect could be observed
by pharmacological inhibition of autophagy, A431 spheroids
were prepared and treated with a single dose of chloroquine or
bafilomycin A1. Spheroids treated in this way showed a similar, al-
though less complete, growth delay (Supplementary Figure S8B).
High levels of ULK1 correlate with a poor prognosis in breast
cancer
To examine the potential importance of ULK1 in cancer prognosis
and treatment, the expression of ULK1 mRNA was examined
in a cohort of 152 breast cancer patients with long-term follow
up. Univariate analysis revealed that patients with the highest
level of ULK1 mRNA had significantly lower relapse-free survival
(log-rank test, P = 0.021) (Figure 7). This association remained
significant when Cox multivariate analysis including oestrogen-
receptor status, patient age, nodal status, tumour size and tumour
grade was performed (P < 0.034).
DISCUSSION
Hypoxia is a common feature of solid tumours, and is an essential
determinant of prognosis and response to therapy. The activation
of the ISR and autophagy represents a mechanism of cancer
cell resistance to hypoxia. In the present study we demonstrated
that the essential autophagy gene ULK1 is a link between these
two mechanisms. We showed that ULK1 is transcriptionally up-
regulated in severe hypoxia and in response to ER stress by the
direct activity of ATF4 at the ULK1 promoter. Previous work has
shown that ATF4 and CHOP can support high levels of autophagic
flux in severe hypoxia through the transcriptional up-regulation of
autophagic machinery proteins MAP1LC3B and ATG5, but does
not support de novo autophagy itself [19,21]. Thus the results
of the present study represents the first example in which ATF4
and the ISR are shown to regulate the expression of an autophagy-
initiating factor and thus to potentially play an important role in
the initiation of de novo autophagy.
It is well known that ULK1 kinase activity is subject to
substantial post-translation regulation [47]. Indeed, to date most
work has focused on the phosphorylation events that regulate
changes in the specific activity of existing ULK1 protein. In
the present study, we found that the total activity of ULK1 is
also subject to substantial transcriptional regulation by ATF4.
When we exposed A431 cells to severe hypoxia the increase in
total ULK1 kinase activity was dependent on the transcriptional
up-regulation of ULK1 by ATF4, although the specific activity
of ULK1 remained unchanged, the massive accumulation of
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Figure 5 ULK1 and ATF4 are required for cancer cell survival in both normoxia and severe hypoxia
A431 (A and D–F) or MCF7 (B) cells were transfected with siRNA against ULK1, ATF4 or a scrambled control sequence (SCR) overnight and exposed to severe hypoxia (A) or normoxia (N) the next
day. After 36 h, A431 (A) or MCF7 (B) cells were stained with Alexa Fluor®-conjugated anti-AV antibody and analysed by flow cytometry. (C) Clonogenicity was assessed by seeding serial dilutions
of A431 cells into 60 mm dishes and exposing them to severe hypoxia for 12 or 24 h. (D) Changes in ATP in severe hypoxia were assessed after exposure to severe hypoxia for 36 h. (E) Caspase
3/7 activity was determined after 24 h in severe hypoxia. (F) HMGB1 protein in the medium was quantified by ELISA after 36 h in severe hypoxia. (G) Intracellular HMGB1 was quantified by Western
blotting after 36 h in severe hypoxia. *P < 0.05, **P < 0.01 and ***P < 0.001 respectively.
ULK1 protein resulted in greatly increased total kinase activity.
In contrast, in MCF7 cells the specific kinase activity of ULK1
markedly increased without protein induction, suggesting that
activity is regulated by post-translational mechanisms. In this
context, ATF4 appeared to play a role in the maintenance of
ULK1 protein level rather than hypoxic up-regulation. Thus,
depending on cell type, either transcriptional up-regulation or
post-translational phosphorylation may be the primary mode of
regulating ULK1 kinase activity. In support of this notion, recent
work has demonstrated that ULK1 expression and autophagy
induction in response to DNA damage were increased through
transactivation of ULK1 by p53 [48].
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Figure 6 Knockdown of ULK1 or ATF4 reduces spheroid growth
A431 cells were transfected with siRNA sequences specific for ULK1, ATF4 or a scrambled control (SCR). The next day, cells were reseeded into round-bottomed 96-well plates at 5000 cells/well. After
24 h spheroid-like structures formed and began to grow (Day 1). (A) Images were taken daily and volume measurements were calculated with ImageJ (NIH) (B). Representative images from n = 4
independent experiments are shown, with n = 10 spheroids in each group for each experiment. Regression analysis was applied to calculate the slope of each curve and P values were calculated by
one-way ANOVA. (C) Spheroids were harvested on day 3 and dissociated using Accutase®. Following staining with Alexa Fluor®-conjugated anti-AV antibody, cells were analysed by flow cytometry.
(D) Alternatively, day 3 spheroids were treated with pimonidazole (PIMO) for 3 h and then fixed and stained by immunohistochemistry using the antibodies indicated. cCasp3, cleaved caspase 3.
In the present study, we demonstrated that ULK1 is required
for autophagy in severe hypoxia, and ATF4 is responsible
for increasing or maintaining ULK1 kinase activity in a cell-
dependent context. We found that knockdown of ULK1 reduced
autophagy induction in severe hypoxia when measured by
Western blotting and immunofluorescence. To our surprise, when
we examined autophagic flux by ImageStream® analysis, we
found that this dependence also occurred in normoxic conditions,
and that ablation of ULK1 or ATF4 in normoxia, severe hypoxia
or three-dimensional cell culture (spheroids) resulted in a similar
reduction in autophagic flux, and a similar enhancement of cell
death. Furthermore, RNAi against ATF4 reduced ULK1 levels
in normoxia as well as hypoxia, suggesting that both ATF4 and
ULK1 are active in the ‘unperturbed’ normoxic condition. In this
vein, it has become apparent that autophagy is crucial for cancer
cell growth and the survival of the oncogenic changes that lead to
cancer development-persistent autophagy is necessary to maintain
a viable pool of mitochondria in H-Ras-expressing cancer cells
and pancreatic cancer cells under otherwise unstressed conditions,
a phenomenon that has been termed ‘autophagy addiction’
[26,27,49,50]. Importantly, it appears that ULK1 is dispensable
in untransformed cells under normal growth conditions and is
necessary for survival only in starvation conditions. ULK1-
knockout mice are viable, showing only mild defects in
haemopoesis [33]. Furthermore, ULK1− / − MEFs (mouse
embryonic fibroblasts) expressing a stable shRNA construct
against ULK2 are viable under normal growth conditions. It is
only when these cells are starved of amino acids and serum that
the ULK1/ULK2 deficiency results in cell death [43].
Previous work has shown that autophagy inhibition can cause
necrosis in apoptosis-deficient cells [25]. Alternatively, there are
a number of systems in which inhibition of autophagy can lead to
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 7 High levels of ULK1 correlate with a poor prognosis in breast
cancer
ULK1 gene expression was considered by univariate analysis and patient samples were ranked
from low to high expression, normalized from 0 to 1, and divided into quartiles. High ULK1
expression correlated with decreased recurrence-free survival. Analyses were performed using
the Spearman’s Rank correlation test and ANOVA. n = 152.
a reduction in apoptosis or cell death [28,48,51–55]. Moreover,
recent work has implicated ULK1/ATG13-mediated autophagy
in promoting DNA-damage-induced cell death, although the
authors failed to show a direct role for ULK1 in this process
[48]. In the present study, we found that ablation of endogenous
ULK1 predisposed cells to die by an unidentified caspase-
3/7-independent mechanism, whereas loss of ATF4 resulted in
apoptotic cell death. One explanation for this result could be
that autophagy is required for the maintenance of a low level of
ATP to initiate caspase activation. Previous work has indicated
that mitophagy is required for apoptosis induction in certain
contexts [52]. Alternatively, it may also be that loss of ULK1
results in elevated ROS (reactive oxygen species) and lysosomal
dysfunction, leading to necroptosis [56–58]. In either scenario, the
residual pool of ULK1 remaining following ATF4 knockdown
might be sufficient to drive caspase-dependent death. In any
case, further study is necessary to identify the mechanism of
this caspase-3/7-independent cell death.
We found a positive correlation between ULK1 mRNA levels
and reduced relapse-free survival in a cohort of breast cancer
patients, implying that ULK1 up-regulation may be a mode of
breast cancer cell survival and tumour progression. Likewise, the
ISR is important in cancer cell survival and tumour maintenance.
Tumour xenografts deficient in ATF4 or expressing a dominant-
negative construct of eIF2α show greatly retarded growth and
enhanced levels of cell death [19,23,24]. Data indicate that ATF4
and the ISR promote cancer cell survival of hypoxia, nutrient
deprivation and oxidative stress in vitro [9,19–22], in part through
the maintenance of high levels of autophagic flux through the up-
regulation of MAP1LC3B and ATG5 [19,21]. The present study
demonstrates for the first time that ATF4 can transcriptionally
up-regulate the autophagy-initiating kinase ULK1 and that ULK1
is crucial for autophagy, mitophagy and cancer cell survival in
normoxia, severe hypoxia and spheroids. Thus, on the basis of
the results of the present study and those of others [26,27], we
speculate that a specific ULK1 inhibitor may be an effective killing
agent against a subset of cancers, with limited toxicity towards
normal cells.
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MATERIALS AND METHODS
Antibodies
Rabbit anti-ULK1 (R600), rabbit anti-ACC, rabbit anti-HMGB1,
rabbit anti-p70S6K, rabbit anti-mTOR, rabbit anti-P-ACC (Ser79),
rabbit anti-P-AMPKα (Thr172), rabbit anti-phospho-p70S6K
(Ser371), rabbit anti-P-Raptor (Ser792) and rabbit anti-Raptor
were obtained from Cell Signaling Technology. A rabbit
polyclonal antibody against ATF4 was obtained from Santa
Cruz Biotechnology. The mouse monoclonal antibody against
MAP1LC3 was purchased from NanoTools. Rabbit anti-HIF2α
antibody was obtained from AbD Serotec. Mouse anti-β-actin was
obtained from Sigma–Aldrich. Mouse anti-CHOP was obtained
from Santa Cruz Biotechnology. Mouse anti-CAIX was prepared
in-house by Cancer Research UK. Rabbit anti-cleaved caspase 3
was obtained from R&D Systems. Mouse anti-pimonidazole was
obtained from Chemicon International.
ULK1 activity assays
Anti-ULK1 antibody
A specific antibody was raised, in sheep, against a peptide
corresponding to a region between the N-terminal kinase domain
and C-terminal-binding domain coupled to KLH (keyhole-limpet
haemocyanin). Antibodies were affinity-purified against peptide
antigen before use.
Immunoprecipitation of ULK1
Extracts were prepared in lysis buffer [50 mM Tris/HCl
(pH 7.5), 1 mM EGTA, 1 mM EDTA, 0.3% CHAPS, 1 mM
sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium
pyrophosphate, 0.27 M sucrose and 0.1% 2-mercaptoethanol]
and clarified by centrifugation at 16000 g for 20 min at 4 ◦C.
To precipitate ULK1, anti-ULK1 antibody was added to cell
extracts and subjected to overnight incubation at 4 ◦C on a
Vibrax shaker. Immunocomplexes were captured on Protein G–
Sepharose (GE Lifesciences) and incubated for a further 1 h at
4 ◦C on a Vibrax shaker. Complexes were washed once in high-
salt buffer (lysis buffer containing 500 mM NaCl), twice in lysis
buffer and twice in assay buffer [20 mM Hepes (pH 7.5), 150 mM
NaCl, 0.1% 2-mercaptoethanol, 25 mM 2-glycerophosphate and
100 μM sodium orthovanadate], before finally resuspending in a
final volume of 24 μl of assay buffer.
ULK1 activity assay
ULK1 activity was assayed at 30 ◦C in a final reaction volume
of 30 μl, containing 10 mM magnesium acetate, 100 μM [γ -
32P]ATP (100–1000 c.p.m./pmol) against 3 μg of MBP. Reactions
were stopped after 30 min by addition of 10 μl of 4×SDS sample
buffer and samples were resolved by 8.0% Bis-Tris SDS/PAGE.
The upper portion of each gel, containing immunoprecipitated
ULK1, was immunoblotted on to Immobilon-P (Millipore) and
probed for ULK1 precipitation. The lower portion of each gel
containing PMBP was imaged by phosphoimaging using an FLA-
7000 PhosphoImager system (Fujifilm UK) and quantified using
MultiGauge software.
Imagestream® analysis of autophagy
Imagestream® (IS100) is a multispectral flow cytometer
combining standard microscopy with flow cytometry (Cronus
Technology). It can acquire up to 100 cells/s, simultaneously
acquiring six images of each cell, including brightfield, scatter and
multiple fluorescent images. Imagestream® was used to analyse
autophagic flux. In brief, MCF7 cells transfected with siRNA for
ULK1 or scrambled sequence were exposed to severe hypoxia
for 24 h. At this point, cells were trypsinized and collected in
15 ml Falcon® tubes. Following washes with assay buffer (1%
FBS/PBS), cells were stained with a Violet live/dead marker
(Invitrogen, L34955 Component A) and a red lysosome-specific
dye (LysoID, Enzo Life Sciences). Cells were then fixed and
permeabilized (eBioscience Fixation and Permeabilization kit)
and stained with mouse anti-LC3 (Nanotools) and Alexa Fluor®
488-conjugated goat anti-mouse IgG (Invitrogen). Cells were
imaged with the Imagestream® apparatus, and images were acqui-
red for each respective channel. Single-stained controls were
included for compensation. Following image acquisition, live
cells were analysed for co-localization of LC3 and lysosomes us-
ing the software package IDEAS 4.0.735. Autophagy levels were
calculated by measuring the percentage co-localization of LC3
and LysoID double-positive cells by plotting these LC3 + Lyso +
(double-positives) for BDS (bright detailed similarity) between
LC3 and lysosomal markers against normalized frequency of
cells. This analysis therefore gave an estimation of the relative
number of autophagolysosomes per cell, in a sample of more than
5000 cells, yielding a powerful assessment of autophagic flux.
Patient details
Tumour samples for 152 individuals were obtained from
a retrospective series of patients with early primary breast
1 To whom correspondence should be addressed (email aharris.lab@imm.ox.ac.uk).
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Table S1 siRNA sequences used for RNAi
siRNA sequences were ordered from Eurogentec and diluted in RNAse-free water to prepare
100 μM stocks. Working solutions were prepared to a final RNA concentration of 20 μM. These
were diluted 1000× in the preparation of lipid constructs for a final concentration of 20 nM RNA
on cells. BNIP3, Bcl2/adenovirus E1B 19 kDa interacting protein 3.
Gene Sense sequence (5′→3′) Working concentration
ATF4 CCACGUUGGAUGACACUUG 20 nM
Scrambled control (BNIP3 SCR) ACGCGACACGCAGGUCGUCAU 20 nM
ULK1
#1 GCACAGAGACCGTGGGCAA 5 nM
#2 CCACGCAGGTGCAGAACTA 5 nM
#3 CGGAGAGCCTGCAGGAGAA 5 nM
#4 GAGCAAGAGCACACGGAGA 5 nM
Table S2 Primers for RT-qPCR
Primers used for RT-qPCR designed using the Universal Probe Library primer design website
(Roche).
Gene Forward primer (5′→3′) Reverse primer (5′→3′)
CHOP AAGGCACTGAGCGTATCATGT TGAAGATACACTTCCTTCTTGAACA
Tubulin α6 (TUBA6) CCCCTTCAAGTTCTAGTCATGC ATTGCCAATCTGGACACCA
ULK1 TCATCTTCAGCCACGCTGT CACGGTGCTGGAACATCTC
cancer who were treated in Oxford, UK between 1990 and
1992. Patients received adjuvant chemotherapy and/or adjuvant
hormone therapy, or no adjuvant treatment. This series is part of a
published series, and full treatment details and demographics has
been described previously [1].
RNA extraction and gene expression profiling
Total RNA was isolated using the TRIzol® method (Invitrogen)
according to the manufacturer’s instructions. mRNA expression
was measured using Affimetrix U133 arrays. RNA was amplified
using the Ambion Illumina Amplification kit. The full protocol
Table S3 Primers for ChIP
RT-qPCR primers designed against genomic regions of the ULK1 promoter, against an upstream
region of chromosome 12 and for the promoter ATF4-target CHOP.
Primer set Forward primer (5′→3′) Reverse primer (5′→3′)
CHOP AGCCAAAATCAGAGCTGGAA ACAAGTTGGCAAGCTGGTCT
CHR12 GGGGCCATTTAAAAGAGTAGTCGT CCTTGTAAAAACCATCAGTCGTCA
ULK1 #1 GTGCGCTGCTTGGCCTAAGTGATG ATCCGCTGGGGAGGAAAGGTTAGC
ULK1 #2 CCAGCGGATTTATGGGCTATGTCG CCGCCCCCACTGCCTGTTCTCCTC
ULK1 #3 AAGGGGAAAAGGAGGGAGGAGGAC GAGCCGGGCGTGACGAACA
ULK1 #4 CTGCGCGGGCGTCTCAG GGCGAGGGCGCATCTCC
ULK1 #5 GCGCCTCCGCCTGAGTCC ATCTCGGGGCGGGGATGC
ULK1 #6 CCAGCCCGACTTTCCTGTCCA CTCCCCCAGACCCCAGTCCA
has been described previously [1]. Data were pre-processed using
gcrma, quantile normalized and logged (base 2) in Bioconductor
(http://www.bioconductor.org). The target sequence of the probes
that corresponded to ULK1 expression was retrieved using
Affymetrix annotation and was 209333_at.
Survival analysis
The end point was relapse-free survival. Univariate and
multivariate analysis was performed. Cox multivariate models
were reduced using step-wise backward likelihood selection. In
univariate analyses, expression of ULK1 and other genes was
considered either as divided in equal quartiles or as continuous
variable ranked, and normalized between 0 and 1. In multivariate
analysis the latter was always considered.
Animal experimentation
All animal experiments were conducted according to Home Office
regulations. When a tumour reached the maximum size (1.44 cm2
surface area) permitted by the Home Office license, the mouse
was killed, and the tumour was excised.
c© The Authors Journal compilation c© 2013 Biochemical Society
Transcriptional regulation of ULK1 by ATF4
Figure S1 ULK1 and CHOP are induced by severe hypoxia
HCT116 (A) and U87 (B) cells were exposed to severe hypoxia (<0.01 % O2) for the times indicated after which cells were harvested and analysed by Western blotting using the antibodies indicated.
A431 (C), MCF7 (D) and HT29 (E) cells were exposed to severe hypoxia for the times indicated after which cells were harvested and analysed RT-qPCR for CHOP mRNA.
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Figure S2 ULK1 is induced in hypoxic xenografts and spheroids
(A) U87 cells were subcutaneously injected into the flanks of SCID (severe combined
immunodeficiency) mice, and treated with bevacizumab (BZ; 10 mg/kg of body weight) or PBS
every 3 days from the day of implantation. After tumours reached end point, mice were killed,
tumours were harvested and mRNA was extracted for analysis with the primers indicated. (B and
C) A431 cells were seeded in round-bottomed 96-well plates at 5000 cells/well overnight. After
24 h spheroid-like structures formed and began to grow (Day 1). Spheroids were collected on the
days indicated and analysed by Western blotting (B) or immunohistochemistry (C) using
the antibodies indicated. PIMO, pimonidazole.
Figure S3 ULK1 degradation in hypoxic MCF7 cells is mediated by the
proteasome
MCF7 cells were treated with (A) 100 nM bortezomib (BORTEZ) or 5 μM MG115, (B) 25 μM
chloroquine (CQ) or 0.1 μM bafilomycin A1 (BAFA1), or (C) 10 μg/ml of each E64D and
pepstatin A (PEP), or 50 μM ZVAD-FMK (ZVAD) and then exposed to severe hypoxia for the
times indicated. Cells were harvested and analysed by Western blotting using the antibodies
indicated.
c© The Authors Journal compilation c© 2013 Biochemical Society
Transcriptional regulation of ULK1 by ATF4
Figure S4 Knockdown of ATF4 reduces CHOP mRNA expression in severe hypoxia
A431 (A) or MCF7 (B) cells were transfected with siRNA against ATF4 or a scrambled control sequence (SCR) overnight and exposed to severe hypoxia (A) or normoxia (N) the following day. After
24 or 48 h, cells were harvested for analysis by RT-qPCR for CHOP mRNA. n = 1.
Figure S5 Ectopic expression of ATF4 is insufficient to drive ULK1 protein
expression
A431 cells were transfected with 0–2000 ng of pCG-empty vector or pCG-ATF4. At 48 h later,
cells were harvested and analysed by Western blotting using the antibodies indicated.
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Figure S6 Severe hypoxia increases ULK1 kinase activity in an ATF4-
dependent manner
A431 cells were exposed to severe hypoxia for 12 or 24 h, after which time cells were harvested
and lysates prepared. An antibody specific to ULK1 was used to immunoprecipitate ULK1, and
detection of ULK1 kinase activity was performed using MBP as a substrate. Images of P-MBP,
Coomassie Blue staining of total MBP and immunoprecipitation of endogenous ULK1 from
A431 (A) and MCF7 cells (B) exposed to severe hypoxia are shown. Alternatively, A431 cells
expressing an inducible shRNA construct against ATF4 (A) or a non-silencing sequence (S) were
treated with doxycycline for 2 days and then exposed to severe hypoxia for the times indicated.
Western blots are shown in (C), confirming depletion of ATF4 and the consequent abrogation
in ULK1 expression. ULK1 specific activity (normalized to ULK1 protein level) is shown in (D),
and P-MBP, Coomassie Blue staining and ULK1 immunoprecipitation are shown in (E).
Figure S7 RNAi silencing of ULK1 mRNA reduces autophagic flux
(A) RNAi silencing of ULK1 mRNA. MCF7 cells were transfected with siRNA against ULK1 or a
scrambled control sequence (SCR) overnight and exposed to severe hypoxia (A) or normoxia
(N) the following day. After 24 or 48 h, cells were harvested for analysis by RT-qPCR for ULK1
mRNA. n = 1. (B) ULK1 is required for autophagy induction in severe hypoxia. MCF7 cells were
transfected with siRNA against ULK1 or a scrambled control sequence (SCR) overnight and
reseeded on to coverslips the next day. Cells were treated with 25 μM chloroquine and exposed
to severe hypoxia for 24 h and then fixed and stained for LC3 (green) and counterstained with
DAPI (4′,6-diamidino-2-phenylindole) (blue).
c© The Authors Journal compilation c© 2013 Biochemical Society
Transcriptional regulation of ULK1 by ATF4
Figure S8 ULK1 protects cancer cells from caspase-3/7-independent cell
death
(A) A431 spheroids lacking ULK1 or ATF4, or controls were harvested on day 3 and stained using
the antibodies indicated and counterstained with haematoxylin. Arrows point to visible nuclear
fragmentation. (B) A431 cells were seeded at 5000 cells/well to a round-bottomed 96-well
plate with MatrigelTM. After 24 h, spheroid-like structures formed and began to grow (Day 1). A
single dose of 25 μM chloroquine (CQ) or 0.1μM bafilomycin A1 (BAF) was administered to
spheroids on day 1. Images were taken daily and volume measurements were calculated with
ImageJ (NIH). n = 10 spheroids in each group. Regression analysis was applied to calculate
the slope of each curve and P values were calculated by one-way ANOVA. UTR, untreated.
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